Christian Récher - Concepedia

Author

Christian Récher

Centre Hospitalier Universitaire de Toulouse ORCID

Also Known As

C Rcher, C Recher, C Récher, C. Recher, C. Récher, Christan Recher, Christian Recher, Christian Récher, Christian Récher, Christian,Robert T.

1.1K

Publications

25.2K

Citations

H-Index

116

Concepts

All Affiliations

Centre Hospitalier Universitaire de Toulouse Inserm Université Toulouse III - Paul Sabatier Hôpital Saint-Louis Institut universitaire du cancer de Toulouse Oncopole

About

Christian Récher is an author at Centre Hospitalier Universitaire de Toulouse specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	39	76	5.2K
2	Health Sciences	22	33	2.5K
3	Blood Transplantation	3	3	113
4	Biochemistry	2	2	242
5	Public Health	1	1	132

Christian Récher

254

Publications

21.9K

Citations

H-Index

Page 1

	Year	Citations
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML Alexander E. Perl, Giovanni Martinelli, Jörge E. Cortes, New England Journal of Medicine	2019	1.2K
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Hervé Dombret, John F. Seymour, Aleksandra Butrym, Blood	2015	1.1K
Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism Thomas Farge, Estelle Saland, Fabienne de Toni, Cancer Discovery	2017	877
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis Arnaud Jaccard, Philippe Moreau, Véronique Leblond, New England Journal of Medicine	2007	514
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure Thomas Prébet, Steven D. Gore, Benjamin Esterni, Journal of Clinical Oncology	2011	475
Ivosidenib and Azacitidine in <i>IDH1</i> -Mutated Acute Myeloid Leukemia Pau Montesinos, Christian Récher, Susana Vives, New England Journal of Medicine	2022	448
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy Ruxanda Moschoi, Véronique Imbert, Marielle Nebout, Blood	2016	438
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study Céline Berthon, Emmanuel Raffoux, Xavier Thomas, The Lancet Haematology Hematological MalignancyTranslational MedicineAcute LeukaemiaMedicineMixed-phenotype Acute Leukemia	2016	425
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel, Blood	2010	383
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice Jean‐Emmanuel Sarry, Kathleen M. Murphy, Robin Perry, Journal of Clinical Investigation Mixed-phenotype Acute LeukemiaImmunologyStem Cell BiologyTumor BiologyMyeloid Neoplasia	2010	380

Page 1